The MS "Wearing-Off" Phenomenon: Separating Symptom Burden from Immunological Change

This episode discusses "The MS 'Wearing-Off' Phenomenon: Separating Symptom Burden from Immunological Change." Dr. Williams introduces the wearing-off phenomenon — a patient experience in which symptoms feel worse as the next anti-CD20 dose approaches. The panel explores whether this represents a true immunological change or a symptom-level phenomenon.

Dr. Bove explains the context: the wearing-off phenomenon was first characterized with natalizumab, where pre-infusion symptom emergence correlated somewhat with lymphocyte dynamics. With B-cell depleting therapies, however, the picture is murkier. Studies tracking step counts via fitness devices have not shown measurable activity changes approaching the next infusion. The wearing-off pattern does not reliably correlate with B-cell levels or a predictable temporal relationship to dosing schedule. The mechanism remains uncertain.

Clinically, Dr. Bove and Dr. Krieger both focus on symptom management rather than altering the dosing schedule. Strategies include addressing underlying fatigue, optimizing sleep, and minimizing symptom triggers in the weeks before the next dose — "filling the tank" through lifestyle modification — rather than interpreting the experience as evidence that the drug is failing.

Dr. Krieger notes this phenomenon partly drives his reluctance to adopt extended interval dosing routinely, as patients describing wearing-off may have their experience amplified if the dosing gap widens. Understanding and validating the symptom burden — even in the absence of a clear immunological explanation — remains central to effective patient partnership.

In the next episode, "Long-Term Management of MS: Monitoring Progression and Supporting Patient Wellness While on Anti-CD20 DMTs," the panel discusses how clinical conversations evolve for patients who have been on B-cell depletion therapy for five or more years.